{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:15:22Z","timestamp":1793531722789,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2320-B-001-004-MY3"],"award-info":[{"award-number":["107-2320-B-001-004-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112502","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T01:11:25Z","timestamp":1638839485000},"page":"112502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice"],"prefix":"10.1016","volume":"146","author":[{"given":"Tien-Ching","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Mae","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Lu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Roffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","article-title":"Emerging PEGylated non-biologic drugs","volume":"24","author":"Park","year":"2019","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.biopha.2021.112502_bib2","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902018000001009","article-title":"Protein PEGylation for the design of biobetters: from reaction to purification processes","volume":"54","author":"Santos","year":"2018","journal-title":"Braz. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.112502_bib3","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1007\/s12274-018-2131-8","article-title":"PEGylation of therapeutic oligonucletides: from linear to highly branched PEG architectures","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res."},{"issue":"7","key":"10.1016\/j.biopha.2021.112502_bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2021.112502_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/103973","article-title":"Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications","volume":"2012","author":"Banerjee","year":"2012","journal-title":"J. Drug Deliv."},{"issue":"4","key":"10.1016\/j.biopha.2021.112502_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"4","key":"10.1016\/j.biopha.2021.112502_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.biopha.2021.112502_bib8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jaip.2021.01.022","article-title":"The COVID-19 Pandemic in 2021: avoiding overdiagnosis of anaphylaxis risk while safely vaccinating the world","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.biopha.2021.112502_bib9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1080\/21645515.2020.1822136","article-title":"COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies","volume":"17","author":"Rele","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"issue":"23","key":"10.1016\/j.biopha.2021.112502_bib10","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.18.02439","article-title":"Antibodies predict pegaspargase allergic reactions and failure of rechallenge","volume":"37","author":"Liu","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112502_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children\u2019s Oncology Group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"9937","key":"10.1016\/j.biopha.2021.112502_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2021.112502_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2019.02.001","article-title":"Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers","volume":"26","author":"Moreno","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-020-0420-0","article-title":"Immunogenicity risk assessment for PEGylated therapeutics","volume":"22","author":"Mora","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2021.112502_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2021.112502_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.biopha.2021.112502_bib17","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","article-title":"The mystery of antibodies against polyethylene glycol (PEG) - what do we know?","volume":"33","author":"Lubich","year":"2016","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.112502_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"issue":"21","key":"10.1016\/j.biopha.2021.112502_bib19","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"issue":"23","key":"10.1016\/j.biopha.2021.112502_bib20","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.112502_bib21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/all.14711","article-title":"Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"issue":"6524","key":"10.1016\/j.biopha.2021.112502_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/science.371.6524.10","article-title":"Pfizer's vaccine raises allergy concerns","volume":"371","author":"de Vrieze","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2021.112502_bib23","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.bja.2020.12.020","article-title":"Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?","volume":"126","author":"Garvey","year":"2021","journal-title":"Br. J. Anaesth."},{"issue":"3","key":"10.1016\/j.biopha.2021.112502_bib24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ymthe.2021.01.030","article-title":"Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines","volume":"29","author":"Moghimi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2021.112502_bib25","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","author":"Khalil","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2021.112502_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/B978-0-444-64081-9.00005-X","article-title":"Immunological responses to PEGylated proteins: anti-PEG antibodies","author":"Elsadek","year":"2020","journal-title":"Polym. Protein Conjug."},{"issue":"1","key":"10.1016\/j.biopha.2021.112502_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pharmaceutics12010015","article-title":"Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice","volume":"12","author":"Chang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2021.112502_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00872","article-title":"Defining natural antibodies","volume":"8","author":"Holodick","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2021.112502_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jcp.s3-13.1.120","article-title":"Antibody affinity: immunogenetic aspects and relationship to immune complex disease","volume":"13","author":"Steward","year":"1979","journal-title":"J. Clin. Pathol. Suppl. R. Coll. Pathol."},{"issue":"2\u20133","key":"10.1016\/j.biopha.2021.112502_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/08820139909061139","article-title":"The influence of antibody functional affinity on the effector functions involved in the clearance of circulating immune complexes anti-BSA IgG\/BSA","volume":"28","author":"Marzocchi-Machado","year":"1999","journal-title":"Immunol. Invest"},{"issue":"6","key":"10.1016\/j.biopha.2021.112502_bib31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4161\/mabs.22216","article-title":"Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies","volume":"4","author":"Mortensen","year":"2012","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.biopha.2021.112502_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/bc980143z","article-title":"Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM","volume":"10","author":"Cheng","year":"1999","journal-title":"Bioconjugate Chem."},{"issue":"7","key":"10.1016\/j.biopha.2021.112502_bib33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/bc100067t","article-title":"Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies","volume":"21","author":"Su","year":"2010","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"10.1016\/j.biopha.2021.112502_bib34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/bc050133f","article-title":"Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles","volume":"16","author":"Cheng","year":"2005","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biopha.2021.112502_bib35","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1038\/ncomms10934","article-title":"Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system","volume":"7","author":"Cheong","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2021.112502_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib37","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2021.112502_bib38","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"7","key":"10.1016\/j.biopha.2021.112502_bib39","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM Is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2021.112502_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.xphs.2018.10.027","article-title":"Time interval of two injections and first-dose dependent of accelerated blood clearance phenomenon induced by pegylated liposomal gambogenic acid: the contribution of PEG-Specific IgM","volume":"108","author":"Wang","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2021.112502_bib42","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1073\/pnas.92.5.1254","article-title":"Kinetic and affinity limits on antibodies produced during immune responses","volume":"92","author":"Foote","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2021.112502_bib43","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.179.6.3841","article-title":"Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid","volume":"179","author":"Poulsen","year":"2007","journal-title":"J. Immunol."},{"issue":"7195","key":"10.1016\/j.biopha.2021.112502_bib44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2021.112502_bib45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm.1966","article-title":"A rapid and efficient single-cell manipulation method for screening antigen-specific antibody\u2013secreting cells from human peripheral blood","volume":"15","author":"Jin","year":"2009","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.molimm.2009.09.009","article-title":"Effects of antibody affinity and antigen valence on molecular forms of immune complexes","volume":"47","author":"Oda","year":"2009","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.104.079277","article-title":"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys","volume":"313","author":"Rojas","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2021.112502_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2018.06.002","article-title":"A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse","volume":"284","author":"McSweeney","year":"2018","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.biopha.2021.112502_bib49","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/acsbiomaterials.7b00147","article-title":"Cross-reactivity of select PEG-binding antibodies to other polymers containing a C-C-O backbone","volume":"3","author":"McCallen","year":"2017","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"2","key":"10.1016\/j.biopha.2021.112502_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.biopha.2021.112502_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221012889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221012889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:46:24Z","timestamp":1779965184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221012889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":51,"alternative-id":["S0753332221012889"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112502","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112502"}}